DUXAP10 and lung carcinoma: A high level of DUXAP10 expression in lung cancer patients was linked to not only lower OS and relapse-free survival (RFS) rates but also larger tumor sizes, advanced tumor stages, lymph node metastasis, and even poor prognosis (Wei et al., 2017; Lin et al., 2021).